Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Details

Instance of

clinical trial

Start time

May 2020

End time

March 2022

Country

Belgium

Main subject

fungal infectious disease, fungemia, systemic inflammatory response syndrome, posaconazole, cytochrome P-450 CYP2C19 Inhibitors, candidiasis, candidemia

clinical trial phase

phase III clinical trial

minimum age

18

number of participants

462

research intervention

fluconazole, posaconazole, trimethoprim, sulfamethoxazole

research subject recruitment status

recruiting

short name

ReSPECT

study type

interventional study

title

A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)